Dan Zhu

Title: The Innovative Contributions of Dan Zhu

Introduction

Dan Zhu is a notable inventor based in Summit, NJ (US), recognized for his significant contributions to the field of biotechnology. With a focus on developing innovative solutions for cancer treatment, he has made strides in engineering antibodies that selectively target tumor cells.

Latest Patents

Dan Zhu holds a patent for the engineering of an antibody designed for tumor-selective binding of CD47. This innovative antibody comprises at least one Fab portion that binds CD47 and another that binds the tumor-associated antigen (TAA) CD20. The unique design allows the Fab portion that binds CD47 to exhibit low affinity for CD47, while the Fab portion that binds CD20 demonstrates high affinity for CD20. This selective binding mechanism enables the antibody to block CD47 interaction with SIRPα in tumor cells, while showing no substantial binding to CD47 in normal cells.

Career Highlights

Dan Zhu is currently employed at Celgene Corporation, where he continues to advance his research in antibody engineering. His work is pivotal in the development of targeted therapies that aim to improve treatment outcomes for cancer patients.

Collaborations

Dan has collaborated with esteemed colleagues, including Haralambos Hadjivassiliou and Jeonghoon Sun, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Dan Zhu's work exemplifies the impact of innovative thinking in the field of biotechnology. His patent for a tumor-selective antibody represents a significant advancement in cancer treatment, showcasing his dedication to improving patient care through scientific innovation.